BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Nventa Biopharmaceuticals Corporation (NVN.TO) to Present at Biotechnology Industry Organization (BIO) 2008 International Convention


6/16/2008 9:49:52 AM

SAN DIEGO, June 16 /PRNewswire-FirstCall/ -- Nventa Biopharmaceuticals Corporation announced today that the Company's vice president of corporate development, Richard Lai Fatt, Ph.D., is scheduled to present a Company overview at the Business Forum during the Biotechnology Industry Organization 2008 International Convention being held in San Diego, California, July 17-20, 2008. The presentation will take place on Wednesday, June 18, 2008, at 3:45 p.m. PDT in Room 5B at the San Diego Convention Center.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080303/LAM023LOGO)

Dr. Lai Fatt will discuss the Company's progress with its lead product candidate, HspE7, a novel compound intended for the treatment of precancerous and cancerous lesions caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. The presentation will not be webcast.

About Nventa Biopharmaceuticals Corporation:

Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The Company is publicly traded on the Toronto Stock Exchange under the symbol NVN.

For more information about Nventa Biopharmaceuticals Corporation, please visit the Company's website located at http://www.nventacorp.com.



CONTACT: Donna Slade, Director, Investor Relations of Nventa
Biopharmaceuticals Corporation, +1-858-202-4945, dslade@nventacorp.com; or
media, Tim Brons of Vida Communication, +1-415-675-7402,
tbrons@vidacommunication.com; or Michael Moore of The Equicom Group,
+1-416-815-0700, ext. 241, mmoore@equicomgroup.com, both for Nventa
Biopharmaceuticals Corporation

Web site: http://www.nventacorp.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->